Skip to main content

Clinical Trials to Treat Adult Metastatic Brain Tumors

Trials 51-66 of 66

Stereotactic Radiation with Sacituzumab Govitecan and Zimberelimab for the Treatment of Patients with Metastatic Triple Negative Breast Cancer with Brain Metastases, TARGET-TNBC Trial
Status: Active
Location: Moffitt Cancer Center, Tampa, Florida
Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
Status: Active
Location: USC / Norris Comprehensive Cancer Center, Los Angeles, California
Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A*11:01 Patients
Status: Active
Location: National Institutes of Health Clinical Center, Bethesda, Maryland
Stereotactic Radiosurgery Dose Escalation in Treating Patients with Brain Metastases
Status: Active
Location: Huntsman Cancer Institute/University of Utah, Salt Lake City, Utah
Fractionated Stereotactic Radiation Therapy in Treating Cancer Patients with Brain Metastases That Has Not Been Removed by Surgery
Status: Active
Location: Montefiore Medical Center-Weiler Hospital, Bronx, New York
Alpelisib and Pembrolizumab for the Treatment of Patients with Locally Advanced, Unresectable, or Metastatic Melanoma or Triple Negative Breast Cancer, SELENA Trial
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Arginine and Whole Brain Radiation Therapy for the Treatment of Patients with Brain Metastases
Status: Active
Location: Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia
Radiosurgery before Surgery for the Treatment of Brain Metastases
Status: Active
Location: Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia
Comparing Stereotactic Radiosurgery Margin Treatment Approaches for the Treatment of Brain Metastases
Status: Active
Location: University of Alabama at Birmingham Cancer Center, Birmingham, Alabama
Personalized Radiation Therapy (PULSAR) for the Treatment of Patients with Extensive-Stage Small Cell Lung Cancer or Brain Metastases, the PRISM Trial
Status: Active
Location: UT Southwestern/Simmons Cancer Center-Dallas, Dallas, Texas
Effect of Azeliragon Combined With Stereotactic Radiation Therapy in Patients With Brain Metastases
Status: Active
Location: See ClinicalTrials.gov
Evaluation of Ascorbate-Meglumine Therapeutic for SRS
Status: Enrolling by Invitation
Location: Duke University Medical Center, Durham, North Carolina
Bevacizumab and Atezolizumab with or without Cobimetinib in Treating Patients with Untreated Melanoma Brain Metastases
Status: Temporarily Closed to Accrual
Location: M D Anderson Cancer Center, Houston, Texas
Atezolizumab, Pertuzumab, and High-Dose Trastuzumab in Treating Patients with Her2-Positive Breast Cancer with Central Nervous System Metastases
Status: Temporarily Closed to Accrual
Location: 3 locations
Nivolumab with Trametinib and Dabrafenib, or Encorafenib and Binimetinib in Treating Patients with BRAF Mutated Metastatic or Unresectable Stage III-IV Melanoma
Status: Temporarily Closed to Accrual
Location: M D Anderson Cancer Center, Houston, Texas
Brain-Directed Stereotactic Radiation Therapy with or without AGulX Gadolinium-Based Nanoparticles for the Treatment of Brain Metastases
Status: Temporarily Closed to Accrual
Location: 2 locations